case_images: PMC11235215_01
case_images: Passage 4 culture images for all 34 infusions. Images were taken with a Leica inverted microscope at 50x magnification. Color variation is due to flask wall thickness, angle, and light. * The product released for infusion #14 was lower than the minimum dose requirement (200 million live cells +-20%) due to the product material harvested at sub-confluency.
case_images: frtra-02-1287508-g001.jpg
case_images: PMC11235215_01_frtra-02-1287508-g001.jpg
case_images: F1
case_images: For infusions, passage #2 cells were thawed, recovered in passage #3, and cultured to passage #4 (Figure 1).
case_images: (A) SCIM-III scores as evaluated by the investigator, and (B) subject's self-evaluation assessment, measured at multiple infusion timepoints and at the end the study, after administration of 34 HB-adMSC infusions. SCIM-III, Spinal Cord Independence Measure III; EOS, end of study.
case_images: frtra-02-1287508-g002.jpg
case_images: PMC11235215_01_frtra-02-1287508-g002.jpg
case_images: F2
case_images: Measure (SCIM-III). SCIM-III scores were calculated using both investigator's assessments as well as patient's self-assessments at multiple visits during the whole treatment period. Measures of the SCIM scores demonstrated functional improvements as early as after the administration of ~10-12 HB-adMSCs infusions (Figure 2). SCIM-III assessment, the subject started at a score of 70, that increased to a score of 79 by the end of the study (EOS), after administration of 34 intravenous infusions of HB-adMSCs (~13% increase from the baseline; Figure 2A). Similar improvements were observed in the subject's self-evaluation SCIM scores (~17% increase from the baseline; Figure 2B).
case_images: (A) Sagittal MRI images (baseline vs. EOS) shows mildly decreased craniocaudal length of the area of T2 abnormality (14.70 mm vs. 12.51 mm), and (B) axial view (baseline vs. EOS) shows minimal increase in the non-edematous portion of the cord at the EOS (post 34 infusions, at month 30) compared to baseline (represented by arrows). EOS, end of study.
case_images: frtra-02-1287508-g003.jpg
case_images: PMC11235215_01_frtra-02-1287508-g003.jpg
case_images: F3
case_images: As observed on the sagittal images, there was a slight decrease in craniocaudal length of T2 abnormality at the EOS, by approximately 2 mm, when compared to baseline (Figure 3A). Also, on the axial images (Figure 3B), there is a suggestion that the non-edematous cord was slightly thicker at the EOS compared to baseline, although this evaluation is limited by the limited number of axial slices through the lesion on both exams.